These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 26093827)

  • 1. Simultaneous Determination of Plasma Deferasirox and Deferasirox-Iron Complex Using an HPLC-UV System and Pharmacokinetics of Deferasirox in Patients With β-Thalassemia Major: Once-daily Versus Twice-daily Administration.
    Lu MY; Wang N; Wu WH; Lai CW; Kuo PH; Chiang PH; Lin KH; Wu TH
    Clin Ther; 2015 Aug; 37(8):1751-60. PubMed ID: 26093827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deferasirox-Iron Complex Formation Ratio as an Indicator of Long-term Chelation Efficacy in β-Thalassemia Major.
    Lu MY; Lin TH; Chiang PH; Kuo PH; Wang N; Wu WH; Lin KH; Wu TH
    Ther Drug Monit; 2017 Apr; 39(2):185-191. PubMed ID: 28141745
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved efficacy and tolerability of oral deferasirox by twice-daily dosing for patients with transfusion-dependent β-thalassemia.
    Chang HH; Lu MY; Liao YM; Lin PC; Yang YL; Lin DT; Chiou SS; Jou ST; Lin KH; Chang TT
    Pediatr Blood Cancer; 2011 Mar; 56(3):420-4. PubMed ID: 21072825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major.
    Galanello R; Piga A; Forni GL; Bertrand Y; Foschini ML; Bordone E; Leoni G; Lavagetto A; Zappu A; Longo F; Maseruka H; Hewson N; Sechaud R; Belleli R; Alberti D
    Haematologica; 2006 Oct; 91(10):1343-51. PubMed ID: 17018383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective.
    Delea TE; Sofrygin O; Thomas SK; Baladi JF; Phatak PD; Coates TD
    Pharmacoeconomics; 2007; 25(4):329-42. PubMed ID: 17402805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction in labile plasma iron during treatment with deferasirox, a once-daily oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia.
    Daar S; Pathare A; Nick H; Kriemler-Krahn U; Hmissi A; Habr D; Taher A
    Eur J Haematol; 2009 Jun; 82(6):454-7. PubMed ID: 19191863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deferasirox pharmacokinetic and toxicity correlation in β-thalassaemia major treatment.
    Allegra S; De Francia S; Cusato J; Pirro E; Massano D; Piga A; D'Avolio A
    J Pharm Pharmacol; 2016 Nov; 68(11):1417-1421. PubMed ID: 27672004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and safety of deferasirox in subjects with chronic kidney disease undergoing haemodialysis.
    Maker GL; Siva B; Batty KT; Trengove RD; Ferrari P; Olynyk JK
    Nephrology (Carlton); 2013 Mar; 18(3):188-93. PubMed ID: 23332024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deferasirox pharmacokinetics evaluation in a woman with hereditary haemochromatosis and heterozygous β-thalassaemia.
    Allegra S; De Francia S; Longo F; Massano D; Cusato J; Arduino A; Pirro E; Piga A; D'Avolio A
    Biomed Pharmacother; 2016 Dec; 84():1510-1512. PubMed ID: 27881236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia.
    Cappellini MD; Cohen A; Piga A; Bejaoui M; Perrotta S; Agaoglu L; Aydinok Y; Kattamis A; Kilinc Y; Porter J; Capra M; Galanello R; Fattoum S; Drelichman G; Magnano C; Verissimo M; Athanassiou-Metaxa M; Giardina P; Kourakli-Symeonidis A; Janka-Schaub G; Coates T; Vermylen C; Olivieri N; Thuret I; Opitz H; Ressayre-Djaffer C; Marks P; Alberti D
    Blood; 2006 May; 107(9):3455-62. PubMed ID: 16352812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state.
    Waldmeier F; Bruin GJ; Glaenzel U; Hazell K; Sechaud R; Warrington S; Porter JB
    Drug Metab Dispos; 2010 May; 38(5):808-16. PubMed ID: 20097723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
    Balocco M; Carrara P; Pinto V; Forni GL
    Am J Hematol; 2010 Jun; 85(6):460-1. PubMed ID: 20513129
    [No Abstract]   [Full Text] [Related]  

  • 13. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload.
    Piga A; Galanello R; Forni GL; Cappellini MD; Origa R; Zappu A; Donato G; Bordone E; Lavagetto A; Zanaboni L; Sechaud R; Hewson N; Ford JM; Opitz H; Alberti D
    Haematologica; 2006 Jul; 91(7):873-80. PubMed ID: 16818273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up.
    Cappellini MD; Bejaoui M; Agaoglu L; Canatan D; Capra M; Cohen A; Drelichman G; Economou M; Fattoum S; Kattamis A; Kilinc Y; Perrotta S; Piga A; Porter JB; Griffel L; Dong V; Clark J; Aydinok Y
    Blood; 2011 Jul; 118(4):884-93. PubMed ID: 21628399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A method to measure deferasirox in plasma using HPLC coupled with MS/MS detection and its potential application.
    Chauzit E; Bouchet S; Micheau M; Mahon FX; Moore N; Titier K; Molimard M
    Ther Drug Monit; 2010 Aug; 32(4):476-81. PubMed ID: 20386360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lifetime cost-utility analyses of deferasirox in beta-thalassaemia patients with chronic iron overload: a UK perspective.
    Karnon J; Tolley K; Vieira J; Chandiwana D
    Clin Drug Investig; 2012 Dec; 32(12):805-15. PubMed ID: 23026844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current status of iron overload and chelation with deferasirox.
    Choudhry VP; Naithani R
    Indian J Pediatr; 2007 Aug; 74(8):759-64. PubMed ID: 17785900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deferasirox pharmacokinetic evaluation in β-thalassaemia paediatric patients.
    Allegra S; Cusato J; De Francia S; Pirro E; Massano D; Piga A; D'Avolio A
    J Pharm Pharmacol; 2017 May; 69(5):525-528. PubMed ID: 27230486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deferasirox pharmacokinetics in patients with adequate versus inadequate response.
    Chirnomas D; Smith AL; Braunstein J; Finkelstein Y; Pereira L; Bergmann AK; Grant FD; Paley C; Shannon M; Neufeld EJ
    Blood; 2009 Nov; 114(19):4009-13. PubMed ID: 19724055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deferasirox--an oral agent for chronic iron overload.
    Vanorden HE; Hagemann TM
    Ann Pharmacother; 2006 Jun; 40(6):1110-7. PubMed ID: 16735647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.